Ikris Pharma Network

What Ikris Pharma Network does

Ikris Pharma Network is a privately held pharmaceutical distribution and access company founded in August 2014 by Mr. Praveen Sikri and headquartered in Noida, India. The company specializes in three core service lines: (1) Named Patient Program management, providing legal pathways for patients in India, South Asia and other underserved markets to access unregistered or unavailable medicines, primarily for rare diseases, oncology and neurology; (2) Clinical Trial Sourcing, providing Reference Listed Drug and comparator supply for Indian CROs and global pharma companies running BA/BE studies and Phase I-IV trials; and (3) international wholesale export of Indian and Bulgarian generic and branded medicines to hospitals, importers, wholesalers, NGOs and government health programs across 150+ countries. Operations are supported by wholly-owned subsidiaries in Belgium (EU-GDP compliant certified pharmaceutical warehouse), Bulgaria (regional HQ and sourcing) and Hong Kong (regional HQ serving Asia), with compliance certifications spanning GDP, ISO, Pharmexcil, FSSAI and MSME.

The revenue model is a mix of transaction-based distribution margin on pharmaceutical product movement, professional services fees for Named Patient Program management and regulatory coordination, and managed services for clinical trial sourcing and comparator supply. Customer segments are horizontal across hospitals, importers/wholesalers, NGOs, government health programs and pharma/CRO buyers, with named partnerships covering eight originator innovators (BioMarin, PTC Therapeutics, Recordati Rare Diseases, Sarepta, Servier, Alexion, Santhera, Gilead). Proprietary technology is limited: a mobile application (Ikris Health+), WhatsApp business integration for B2B communication, and a databases-driven resource center; no API platform or AI/ML capabilities are disclosed. The company also owns and distributes a single branded specialty product, Triokris (Trientine Hydrochloride 250 mg) for Wilson's Disease, manufactured in a USFDA-approved facility.

Ownership is founder-led with no external private equity or venture capital investment disclosed; key domestic and international legal entities are wholly owned. The operating model is small-team (11–50 employees) with lean regional entities, relying on direct enterprise sales, government and NGO tenders, and partnership-driven Named-Patient Import channels. The company is positioned as a specialist intermediary between global originator innovators and emerging-market patients, leveraging regulatory expertise and cold-chain logistics rather than technology differentiation.

Name

Ikris Pharma Network

Legal name

Ikris Pharma Network Pvt. Ltd.

Website

https://ikrispharmanetwork.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

Ikris Pharma Network is a Noida, India-based pharmaceutical distributor founded in 2014 by Praveen Sikri, specializing in Named Patient Programs, clinical trial RLD sourcing, and international generic medicine exports to hospitals, importers, NGOs, and government health programs across more than 150 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Health Services (8000)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industries

Third-Party Logistics (3PL) & Warehousing for Pharmaceuticals (HLAIAJAL), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Pharmaceutical distribution
• Named patient programs
• Clinical trial sourcing
• Generic medicine export
• Rare disease medicines

Headquarters

HQ city

Noida

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Distribution and Export: Ikris Pharma Network generates revenue through the export and distribution of pharmaceutical products including generic medicines, branded medicines, rare disease medicines, and specialty pharmaceuticals to hospitals, healthcare institutions, importers, wholesalers, NGOs, and government health programs across 150+ countries worldwide.
2. Named Patient Program Services: Revenue generated from facilitating Named Patient Programs for patients requiring access to unregistered or unavailable medicines, including regulatory coordination, sourcing, and logistics services.
3. Clinical Trial Sourcing Services: Services for pharmaceutical companies and CROs including Reference Listed Drug (RLD) sourcing, comparator drug supply, and clinical trial material logistics for BA/BE studies and Phase I-IV trials.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Ikris Pharma Network is a pharmaceutical distribution and export company that sources, supplies, and delivers medicines across 150+ countries. Its core offerings include Named Patient Programs for accessing unregistered medicines, clinical trial sourcing of Reference Listed Drugs and comparators, international wholesale export of Indian generic and branded medicines, and Real World Data collection from Managed Access Programs. The company also distributes its own branded product Triokris (Trientine Hydrochloride) for Wilson's Disease and operates the Ikris Health+ mobile app providing global medicine database access.

Product overview

Ikris Pharma Network operates as a pharmaceutical services company offering a portfolio of interconnected services centered on medicine access and distribution. The core offerings include Named Patient Management (for accessing unapproved medicines), Clinical Trial Sourcing (RLD sourcing for pharmaceutical research), Indian Generic Medicines (global export of cost-effective generics), and Real World Data collection services. The company also manufactures and distributes its own branded product Triokris (Trientine Hydrochloride 250mg capsules) for Wilson's Disease treatment. An Ikris Health+ mobile app provides a global medicine database for patients and healthcare providers. Services span therapeutic areas including Oncology, Hepatology, Neurology, Transplant, Hematology, Immunology, Nephrology, and Rare Diseases.

Differentiator

Problem solved

Functional benefit

Brands

• Triokris: Trientine Hydrochloride Capsules USP 250 mg for Wilson's Disease treatment, manufactured in USFDA-approved facility and distributed by Ikris Pharma Network.

Products and services

• Triokris (Trientine Hydrochloride Capsules USP 250 mg) A copper-chelating agent indicated for the treatment of Wilson's Disease, especially in patients who cannot tolerate D-Penicillamine. Manufactured in a USFDA-approved facility and distributed by Ikris Pharma Network.
• Named Patient Management Service helping patients and healthcare providers access life-saving medications not available or registered in their home country through legal regulatory pathways. Covers major therapeutic areas including Oncology, Hepatology, Neurology, Transplant, Hematology, Immunology, and Nephrology.
• Clinical Trial Sourcing Provides Reference Listed Drug (RLD) sourcing and clinical trial supply services, handling procurement and logistics for medicines and comparators needed in drug development for research institutions and CROs. Includes temperature-sensitive study drug handling for BA/BE studies and Phase I-IV trials.
• Indian Generic Medicines Export Exporting medicinal products to over 150+ countries, delivering quality generic medicines from India to patients, hospitals, resellers, and pharmacies globally through established network with leading Indian manufacturers.
• Real World Data Collects Real-World Data (RWD) through Managed Access Programs for unlicensed or early-access therapies, providing insights for pharmaceutical companies, market access firms, regulators, and distributors.
• Ikris Health+ App Mobile application offering access to a wide range of medicines through a comprehensive global medicine database, providing essential medical information and support to patients and healthcare providers.

Quantifiable outcome

• Over 10,000 patients served with rare diseases and critical conditions
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Eight partnerships are on record, tiered core.

• Santhera PharmaceuticalscoreStrategic or Co-development Partner · 28 August 2025Ikris Pharma Network received official authorization from Santhera Pharmaceuticals to facilitate patient access to their medicines for Duchenne Muscular Dystrophy (DMD) in India. In 2025, Santhera signed an exclusive agreement appointing Ikris to manage the distribution of a DMD therapy in India. Access facilitated through Named-Patient Import pathway.
• Gilead SciencescoreStrategic or Co-development Partner · 1 January 2025Ikris Pharma Network has been authorized by Gilead Sciences, Inc. to support patient access to specific therapies for HR+/HER2- metastatic breast cancer and metastatic triple-negative breast cancer in India. Access facilitated through Named-Patient Import pathway.
• BioMarin Pharmaceutical InccoreStrategic or Co-development Partner · 1 January 2022Ikris Pharma Network is authorized by BioMarin to provide access to the company's medicines to Indian patients through Named-Patient Import. BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery, developing and commercializing targeted therapies that address the root cause of genetic conditions.
• PTC TherapeuticscoreStrategic or Co-development Partner · 1 January 2022Ikris Pharma Network is authorized by PTC Therapeutics to provide access to their medicines to Indian patients through Named-Patient Import. PTC Therapeutics is a pharmaceutical company focused on developing treatments for rare diseases.
• Recordati Rare DiseasescoreStrategic or Co-development Partner · 1 January 2022Ikris Pharma helps in accessing Recordati Rare Disease medicines for patients in India, Nepal, Pakistan & Sri Lanka through strategic alliances and exclusive distribution agreement. Patients from these countries can directly contact Ikris for Orphan Europe products.
• Sarepta TherapeuticscoreStrategic or Co-development Partner · 1 January 2022Ikris Pharma Network is authorized by Sarepta Therapeutics to provide access to their medicines to Indian patients through Named-Patient Import. Sarepta Therapeutics is focused on advancing precision genetic medicine.
• Servier PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2022Ikris Pharma Network is authorized by Servier to provide access to their medicines to Indian patients through Named-Patient Import. Servier is dedicated to driving therapeutic progress.
• Alexion PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2022Ikris Pharma Network is authorized by Alexion Pharmaceuticals to provide access to Asfotase Alfa to Indian patients through Named-Patient Import basis. Every day builds a better tomorrow according to Alexion's mission.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• World Courier (Cencora): Part of Cencora (formerly AmerisourceBergen), World Courier provides specialty pharma logistics and cold-chain distribution globally; a scaled incumbent in the same logistics/cold-chain category Ikris operates in, albeit with much broader resources.
• Movianto (Owens & Minor): European pharmaceutical distribution and logistics specialist with cold-chain capability — comparable to Ikris's Belgium-based GDP-compliant distribution operation but at significantly larger scale.
• Almac Group: Global contract pharmaceutical services provider with clinical trial supply and distribution services — a larger incumbent offering overlapping capabilities in clinical trial supply and pharmaceutical services.

Direct peers

• Myoderm: US-based specialty pharmaceutical distributor focused on comparator sourcing and clinical trial supply — a direct functional peer in the RLD/comparator and clinical trial distribution segment.
• Clinigen Group: UK-headquartered global pharmaceutical services firm running Named Patient Programs, clinical trial supply, and unlicensed medicine access across multiple regions — the most direct functional comparison to Ikris's NPP and trial-sourcing franchise.
• Inceptua Group: Specializes in Named Patient Programs, early access, and clinical trial supply for pharma companies globally — overlaps directly with Ikris on NPP, RLD sourcing, and comparator supply.
• Trident Pharmaceuticals: Specialty pharmaceutical company providing Named Patient and managed access distribution, comparators and clinical supply services to pharma and biotech — a closer smaller-scale peer in the NPP/comparator niche.

Emerging players

• Caldic Life Sciences: Specialty distributor and solutions provider for life sciences including pharma raw materials and intermediates in Europe/Asia — partial overlap with Ikris on specialty pharma distribution and cold-chain solutions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/IkrisPharma
• Facebookfacebook.com/Ikrispharmanetwork
• LinkedInlinkedin.com/company/ikris-pharma-network

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ikris Pharma Network